Immunosuppressants in systemic necrotizing vasculitides

Israel Medical Association Journal

Volumn 3, Issue 10, 2001, Pages 749-754

  Guillevin, Loïc ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Churg Strauss syndrome; Cyclophosphamide; Immunosuppressants; Polyarteritis nodosa; Wegener's granulomatosis

Indexed keywords

15 DEOXYSPERGUALIN; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LAMIVUDINE; LEFLUNOMIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TUMOR NECROSIS FACTOR ANTIBODY;

ALLERGIC REACTION; BLADDER DISEASE; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; HEMORRHAGIC CYSTITIS; HUMAN; HYPERSENSITIVITY; LIVER TOXICITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; OVARY DISEASE; PLASMAPHERESIS; PNEUMONIA; POLYARTERITIS NODOSA; REVIEW; SYSTEMIC DISEASE; SYSTEMIC VASCULITIS; WEGENER GRANULOMATOSIS;

CHURG-STRAUSS SYNDROME; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROGNOSIS; TREATMENT OUTCOME; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0035691812     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Long term follow-up study of polyarteritis nodosa
2. Clinical features, prognosis and response to treatment in polyarteritis
3. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa
4. Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis
5. Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years
6. Wegener granulomatosis: An analysis of 158 patients
7. A multicentre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (CYCAZAREM)
8. Treatment of polyarteritis nodosa and microscopic polyangiitis
9. Kawasaki syndrome with intravenous gammaglobulin
10. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients
11. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients
12. Disease assesssment and management of the vasculitides
13. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients
14. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: Comparison of steroids and oral or pulse cyclophosphamide in 25 patients
15. Treatment of systemic vasculitis with cyclophosphamide and steroids: Daily oral low-dose cyclophosphamide administration after failure of a pulse intravenous high-dose regimen in four patients
16. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis
17. Cyclophosphamide pulses in the treatment of rheumatic diseases: An update
18. Pharmacokinetics of cyclophosphamide in patients with systemic necrotizing angiitis
19. New developments in the treatment of systemic vasculitis
20. Classification and management of necrotising vasculitides
21. Mixed cryoglobulinemia secondary to hepatitis C virus infection
22. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis
23. Treatment of primary systemic vasculitis
24. Effectiveness of cyclophosphamide pulse treatment in Wegener's granulomatosis
25. Microscopic polyarteritis: Presentation, pathology and prognosis
26. Microscopic polyangiitis: Clinical and laboratory findings in 85 patients
27. Renal vasculitis: Microscopic polyarteritis and Wegener's granulomatosis
28. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate
29. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole
30. A staged approach in the treatment of Wegener's granulomatosis: Induction with glucocorticoids and daily cyclophosphamide switching to methorexate for remission maintenance
31. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy
32. Leflunomide, a new promising agent in maintenance of remission in Wegener's granulomatosis
33. Immune ablation with peripheral stem cell rescue in Wegener's: Systemic vasculitis
34. Intravenous immunoglobulin as sole therapy for systemic vasculitis
35. Monoclonal-antibody therapy in systemic vasculitis
36. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients
37. Polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: Clinical aspects, neurologic manifestations, and treatment
38. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies
39. Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchanges, meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis
40. Therapeutic plasma exchange in renal diseases